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Abstract A mitochondrial cytochrome P450 fraction catalyzing 
hx- and 27-hydroxylation but not 24-hydroxylation of 25- 
hydroxyvitamin D3 was purified from pig kidney. The ratio 
between the la-  and 27-hydroxylase activities was the same in 
all purification steps including a side fraction. Attempts to 
separate the l~z- and 27-hydroxylase activities were unsuccess- 
ful. A monoclonal antibody directed against purified pig liver 
CYP27 recognized a protein of the same apparent Mr and 
immunoprecipitated both the hx- and 27-hydroxylase activities 
towards 25-hydroxyvitamin D3 in the purified kidney enzyme 
fraction as well as in a solubilized, crude cytochrome P450 
extract considered to represent the major part of the 25- 
hydroxyvitamin D3 hydroxylases in kidney mitochondria. Taken 
together, the results from the purification and the experiments 
with CYP27 antibody, substrate inhibition, and recombinant 
expressed human liver CYP27 strongly indicate that CYP27 is 
able to catalyze la-hydroxylation but not 24-hydroxylation of 
25-hydroxyvitamin D3 in kidney. In conclusion, the results 
provide evidence for a role for CYP27 as a major renal 
mitochondrial 25-hydroxyvitamin D3 la-hydroxylase. 
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1. Introduction 
From a regulatory point of view, the hx-hydroxylation of
25-hydroxyvitamin Da is the most important reaction in the 
overall metabolism of vitamin Da. The lct-hydroxylation 
takes place primarily in the kidney and the enzyme is known 
to be a cytochrome P450 located in the inner mitochondrial 
membrane [1-3]. Several efforts have been made to try to 
characterize an assumed specific mitochondrial let-hydroxyl- 
ase in kidney - so far without success [3-7]. There are two 
additional mitochondrial cytochromes P450, CYP24 and 
CYP27, that are active towards 25-hydroxyvitamin Da [8,9]. 
CYP24 catalyzes the 24-hydroxylation of 25-hydroxyvitamin 
Da in kidney and intestine but is inactive in the hx-hydroxyla- 
tion. The activated vitamin D3 product, lct,25-dihydroxyvita- 
min D3, is known to regulate the 24- and la-hydroxylase 
activities reciprocally. Thus, CYP24 is induced whereas the 
mitochondrial ltx-hydroxylase activity in kidney is suppressed 
by this compound [8,10-13]. CYP27 catalyzes 27-hydroxyla- 
tion of C27-steroids and 25-hydroxyvitamin D3 and 25- 
hydroxylation of vitamin D3 in liver [10,14,15]. mRNA for 
CYP27 is distributed in several tissues including kidney [15]. 
Recently, Ax6n et al. [14,16] reported the surprising finding 
that purified liver mitochondrial CYP27 and recombinant ex- 
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pressed human CYP27 were able to catalyze the let-hydroxyl- 
ation of 25-hydroxyvitamin Da. The expression of CYP27 
mRNA in rat kidney was found to be suppressed by la,25- 
dihydroxyvitamin Da, indicating a coordinate regulation of 
CYP27 mRNA levels and mitochondrial lct-hydroxylase ac- 
tivity by lct,25-dihydroxyvitamin D3 in kidney [16]. The re- 
sults suggest a possible role of CYP27 as a renal la-hydro- 
xylase and raise further questions on the catalytic properties 
of CYP27 towards 25-hydroxyvitamin D3 in kidney. 
The present investigation reports evidence that renal 
CYP27 is able to catalyze the la-hydroxylation but not 24- 
hydroxylation of 25-hydroxyvitamin Dz and that most of the 
let-hydroxylase activity in kidney appears to be associated 
with CYP27. 
2. Materials and methods 
2.1. Purification of cytochrome P450 catalyzing la-hydroxylation 
Kidney cortex mitochondria were prepared from 20-25 kg of kid- 
ney from castrated pigs [6,17]. Phosphate buffers, used as the potas- 
sium salt, contained 1 mM dithiothreitol and 0.25 mM PMSF. Mi- 
tochondria were suspended in 10 mM phosphate buffer, pH 7.4, to a 
protein concentration f 25 mg/ml, homogenized and allowed to stand 
at 4°C overnight. The mitochondrial suspension was sonicated for 
3 rain at intervals of 15 s and centrifuged at 100000×g for 30 min. 
The precipitate was dissolved and homogenized in 0.1 M phosphate, 
pH 7.4, containing 20% glycerol and 0.1 mM EDTA. All buffers in 
the purification procedures contained 20% (v/v) glycerol and 0.1 mM 
EDTA unless otherwise stated. The suspension was diluted to a pro- 
tein concentration f 20 mg/ml, sodium cholate was added to 0.8% (w/ 
v), the suspension was stirred gently for 1 h at 4°C, and then centri- 
fuged at 100000×g for 30 min. The 100000×g supernatant was 
subjected to chromatography on DEAE-Sepharose CL6B (8× 15 
cm) equilibrated with 0.1 M phosphate buffer, pH 7.4, containing 
0.5% sodium cholate. The non-bound material was applied to an 
aminohexyl-Sepharose column (5×30 cm), equilibrated with 0.1 M 
phosphate buffer, pH 7.4, containing 0.4% sodium cholate. The cyto- 
chrome P450 fraction eluted with 0.1 M phosphate buffer, pH 7.4, 
containing 0.2% (w/v) polyoxyethylene 10lauryl ether (POELE) was 
diluted 4-fold with 20% glycerol containing 0.1 mM EDTA and sub- 
jected to chromatography on hydroxyapatite (column, 4x20 cm), 
equilibrated in 10 mM phosphate buffer, pH 7.4, containing 0.2% 
POELE. The hydroxyapatite column was washed with 25 mM phos- 
phate buffer, pH 7.4, containing 0.2% POELE. The cytochrome P450 
fraction eluted with 150 mM phosphate buffer, pH 7.4, containing 
0.2% POELE, was concentrated, dialyzed against 20 mM Tris-acetate 
buffer, pH 8.0, containing 0.4% POELE and then subjected to Q- 
Sepharose chromatography. The column (1.6×30 cm) was equili- 
brated in the same buffer as used for dialysis and was eluted in a 
linear gradient of sodium acetate (04).5 M) in the equilibrating buffer. 
The cytochrome P450 eluted with 85 mM sodium acetate was dialyzed 
against 10 mM phosphate buffer, pH 7.0, containing 0.1% sodium 
cholate, and subjected to chromatography on Q-Sepharose (column, 
1.6 × 20 cm) equilibrated and washed in the same buffer as used for 
dialysis. The column was eluted with sodium acetate gradients (04).1, 
0.1, 0.14).3, 0.3 M) in the equilibrating buffer. Detergents were re- 
moved and the final cytochrome P450 fraction was dialyzed as de- 
scribed [17]. 
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2.2. Preparation of a crude kidney mitochondrial cytochrome P450 
extract active in la-, 24-, and 27-hydroxylations 
Mitochondrial cytochrome P450 from 1 kg of pig kidney was cho- 
late solubilized as described above and only partially purified by oc- 
tylamine-Sepharose and hydroxyapatite chromatography [18]. 
saline). An alkaline phosphatase detection system (Bio-Rad) was 
used to visualize the immune complexes. 
3. Results and discussion 
2.3. Purification of human liver CYP27 expressed in E. coli 
Glycerol stocks of pTrc 27H-transformed JM 105 cells served as an 
inoculum for all expression experiments [14]. The membranes i olated 
from 1 1 of culture were diluted to a protein concentration of 20 mg/ 
ml with 100 mM phosphate buffer, pH 7.4, containing 20% glycerol, 
0.1 mM EDTA and 0.25 mM PMSF. The membrane proteins were 
solubilized by addition of 0.8% sodium cholate and centrifuged at 
100 000 × g for 60 min [14]. The supernatant was dialyzed against 50 
mM phosphate buffer, pH 7.4, containing 20% glycerol, and used as a 
source of human liver CYP27. 
2.4. Incubation procedures 
25-Hydroxyvitamin D3, 25 ktg in 25 /al acetone, was incubated at 
37°C for 20-60 min with 0.5 nmol of cytochrome P450 or 0.5 mg of 
solubilized membrane protein from E. coli, 4 nmol of ferredoxin, 0.4 
nmol of ferredoxin reductase, and 1 ~mol of NADPH in a total 
volume of 1 ml of 50 mM Tris-acetate buffer, pH 7.4. Incubations 
were terminated, extracted and analyzed by SP- and RP-HPLC as 
described previously [9]. 
2.5. Antibody production and hwubations with antibody-coupled 
Sepharose 
A monoclonal antibody, MAb 26C5, raised against pig liver mito- 
chondrial CYP27 [9] and an irrelevant monoclonal antibody, MAb 
25H6 [19], raised against pig liver microsomal vitamin D3 25-hydrox- 
ylase were those produced and used in previous reports from this 
laboratory. Polyclonal antibodies raised against an unknown pig kid- 
ney mitochondrial protein with a molecular weight of approx. 55 kDa, 
were raised in New Zealand White rabbits. The antigen was prepared 
by SDS-PAGE and following transfer to nitrocellulose sheets the 
bands were visualized by india ink staining. The band corresponding 
to the 55 kDa protein was cut out, dissolved in DMSO, emulsified in 
an equal volume of Freund's complete or incomplete adjuvant and 
used for multiple immunization. The antibodies were purified from 
rabbit serum on protein A-Sepharose [20]. The antibodies were sepa- 
rately coupled to CNBr-Sepharose. Cytochrome P450 (0.5 nmol) was 
incubated for 1 h with the indicated amounts of Sepharose-bound 
antibody in 0.4 ml of 50 mM Tris-acetate buffer, pH 7.4, containing 
20% glycerol, 0.1 mM EDTA, and 0.5% (w/v) CHAPS. Inactivated 
Sepharose without antibody was used as a control. The Sepharose was 
washed once with the same buffer without CHAPS and pooled. The 
reaction mixture, 1 ml, was incubated for 1 h at 37°C, terminated, 
extracted and analyzed as described [9]. 
2.6. Other methods 
Adrenodoxin and adrenodoxin reductase from bovine adrenal mi- 
tochondria were prepared as described [17]. Protein and cytochrome 
P450 determinations, SDS-PAGE and silver staining were performed 
as described [21~4]. Immunoblotting was performed as described 
[20], except hat the blot was incubated with the monoclonal antibody 
(10 pg/ml) or antiserum (diluted 300-fold with phosphate-buffered 
3.1. Purification of lot-hydroxylating cytochrome P450 from 
pig kidney mitochondria 
A cytochrome P450 fraction, active in let-hydroxylation of 
25-hydroxyvitamin Dz, was isolated from kidney mitochon- 
dria of castrated pigs by solubilization with sodium cholate 
and chromatography on DEAE-Sepharose, aminohexyl- 
Sepharose, hydroxyapatite, and Q-Sepharose in two steps. 
The enzyme fraction also catalyzed 27-hydroxylation but 
not 24-hydroxylation of 25-hydroxyvitamin D3. The specific 
cytochrome P450 content varied between 2.4 and 3.8 nmol 
cytochrome P450 mg -1 protein in different preparations. On 
silver-stained SDS-PAGE (Fig. 1A) all preparations howed 
one major protein at 53 kDa and a minor one at 55 kDa in 
the molecular weight region for cytochrome P450. Owing to 
the very low content of cytochrome P450 and relative abun- 
dance of other kinds of hemoproteins in kidney mitochondria, 
it was important o purify the let-hydroxylase protein by mea- 
suring the catalytic activity throughout each step in the pur- 
ification procedure. Attempts to separate the lct- and 27-hy- 
droxylase activities by various chromatographic methods were 
unsuccessful. No let- or 27-hydroxylase activity was detected 
in any of the side fractions with the exception of the last 
chromatographic step. The ratio between the 27- and let- 
hydroxylase activity towards 25-hydroxyvitamin D3 was 
about 4:1 in all purification steps and in all preparations 
(Table 1). The side fraction from the last chromatographic 
step catalyzed both let- and 27-hydroxylation of 25-hydroxy- 
vitamin D 3. The ratio between 27- and let-hydroxylase activ- 
ity was also 4:1 in this fraction although the rate of hydro- 
xylation and the cytochrome P450 content were several-fold 
lower than in the main fraction. 
3.2. A monoclonal antibody aga&st CYP27 inhibits renal 
la-hydroxylase activity 
SDS-PAGE and immunoblotting analyses of the purified 
cytochrome P450 fraction were performed with a monoclonal 
antibody (MAb 26C5) raised against pig liver CYP27 [9] and 
with a polyclonal antibody (HP3) against a 55 kDa pig kidney 
protein present in the final cytochrome P450 fraction of all 
preparations. Fig. 1B shows that the antibodies recognized 
protein with Mr of 53 kDa and 55 kDa, respectively. The 
two antibodies were separately coupled to Sepharose and in- 
cubated with the purified cytochrome P450 fraction. After 
Table 1 
Catalytic activities of purified pig kidney mitochondrial cytochrome P450 catalyzing lct- and 27-hydroxylation f 25-hydroxyvitamin Dz
P450 content 
(nmol mg -1 
protein) 
25-Hydroxyvitamin D3 Ratio 
27-hydroxylation I c~-hydroxylation 27:1 ct 
(pmol min -1 (pmol min -1 (pmol min -1 (pmol min -1 
mg -1 protein) nmo1-1 P450) mg -1 protein) nmo1-1 P450) 
Prep. I 2.6 143 33 33 8 4.3 
Prep. II 2.4 256 58 73 17 3.5 
Prep. III 3.7 516 141 118 32 4.4 
Prep. IV 3.0 133 49 29 11 4.6 
Incubations were terminated, extracted and analyzed as described in Section 2. The results from four preparations are shown. 
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Fig. 1. SDS-PAGE of partially purified CYP27 from pig kidney mitochondria (A) and Western blotting using antibodies against pig liver 
CYP27 and the 55 kDa protein (B). (A) Lanes: 1, a mixture of CYP1A2 (55 kDa) and 2B4 (48 kDa) from rabbit liver microsomes used as Mr 
standards (1 ktg of each); 2, purified kidney mitochondrial cytochrome P450 (10 gg). (B) Partially purified CYP27 from pig kidney mitochon- 
dria (5 ktg/lane) was subjected to SDS-PAGE, electrophoretic transfer and immunoblotting with different antibodies. Lanes: 1, preimmune ser- 
um; 2, anti-55 kDa (HP3); 3, anti-CYP27 (MAb 26C5). 
incubation, the antibody-Sepharose was removed and the 
supernatant assayed in a reconstituted system for let- and 
27-hydroxylase activity towards 25-hydroxyvitamin D3. As a 
control, Sepharose was coupled to an irrelevant monoclonal 
antibody directed against pig liver microsomal vitamin D3 25- 
hydroxylase (MAb 25H6) [19]. Increasing amounts of MAb 
26C5 but not HP3 or the irrelevant antibody were able to 
bind more than 90% of both the let- and the 27-hydroxylase 
activities towards 25-hydroxyvitamin D3. 
A separate set of experiments was carried out in an attempt 
to examine how much of the total let-hydroxylase in kidney 
mitochondria s represented by the lct-hydroxylase in the pur- 
ified cytochrome P450 preparation. For this purpose, a solu- 
bilized, crude kidney mitochondrial cytochrome P450 extract 
considered to contain most of the mitochondrial la-,  24- and 
27-hydroxylase activities was prepared. The cytochrome P450 
had to be partially purified in order to achieve a meaningful 
and accurate assay of the hydroxylase activities towards 25- 
hydroxyvitamin D3. The monoclonal antibody raised against 
CYP27 (MAb 26C5) was incubated with the partially purified 
cytochrome P450 fraction. As shown in Fig. 2A, more than 
90% of the ltx-hydroxylase and 27-hydroxylase activities were 
immunoprecipitated by increasing amounts of the antibody. 
The 24-hydroxylase activity was not immunoprecipitated in 
the same way. The lowest amount of antibody decreased the 
24-hydroxylase activity, however, the activity was not further 
decreased by greater amounts of the antibody. A possible 
explanation for this finding might be that the antibody could 
bind to a part of CYP24 which is aggregated together with 
CYP27, whereas the non-aggregated CYP24 is not bound by 
the antibody. 
3.3. Substrate for CYP27 inhibits lo~-hydroxylation 
Since the ratio between the let- and 27-hydroxylase activ- 
ities remained essentially constant during purification and 
since the purification and antibody experiments indicated 
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Fig. 2. Effects of antibodies (A) and CYP27 substrate (B) on la- (e), 24- (A) and 27-hydroxylation (x) of 25-hydroxyvitamin D3 by a solu- 
bilized, crude kidney mitochondrial cytochrome P450 extract. (A) Cytochrome P450 (0.5 nmol) was incubated in a total volume of 1 ml with 
the indicated amounts of Sepharose-bound antibody against pig liver CYP27 (MAb 26C5) or irrelevant antibody against pig liver microsomal 
vitamin D 25-hydroxylase (MAb 25H6) and assayed for hydroxylase activities as described in Section 2. The 100% of control value was for la- 
hydroxylation 13 pmol nmo1-1 min -1, for 24-hydroxylation 5 pmol nmo1-1 min -1 and for 27-hydroxylation 79 pmol nmo1-1 min -1. (B) 25-Hy- 
droxyvitamin Da (200 ~tM) was incubated in a reconstituted system as described in Section 2 with the indicated concentrations of vitamin Da. 
that most of the renal mitochondrial let-hydroxylase activity 
is associated with CYP27, further comparisons with this en- 
zyme were made. Addition of increasing amounts of vitamin 
D3, a known substrate for CYP27, to the partially purified 
lct-hydroxylase system decreased both the le t -and  27- 
hydroxylase activities towards 25-hydroxyvitamin Da in a par- 
allel fashion. Vitamin Da together with 25-hydroxyvitamin Da
in equimolar concentrations decreased the let- and 27- 
hydroxylase activities by 50%, as would be expected if a single 
enzyme catalyzed both reactions. In contrast, the 24-hydro- 
xylase activity was not inhibited but rather slightly increased 
by the addition of vitamin D3 to the reconstituted system 
(Fig. 2B). 
The results provide further evidence that the activity of let- 
hydroxylase but not that of 24-hydroxylase is associated with 
CYP27 in kidney mitochondria. 
3.4. Recombinant expressed human liver CYP27 in E. coli 
catalyzes let-hydroxylation but not 24-hydroxylation 
Since it has been reported that recombinant expressed hu- 
man liver CYP27 catalyzes 24-hydroxylation of vitamin Dz 
and vitamin Dz [25], experiments were performed with 25- 
hydroxyvitamin D3 and human liver CYP27 recombinantly 
expressed in pTrc27H-transforrned E. coli [14]. The expression 
of human CYP27 was induced by isopropyl [3-D-thiogalacto- 
pyranoside and membrane proteins were solubilized with so- 
dium cholate. Solubilized CYP27 protein reconstituted with 
adrenodoxin and adrenodoxin reductase showed hx-hydroxyl- 
ase activity (10 pmol min -1 nmo1-1 P450) and 27-hydroxylase 
activity (8 pmol min -1 nmo1-1 P450) but not 24-hydroxylase 
activity ( < 0.1 pmol min -1 nmo1-1 P450) towards 25-hydro- 
xyvitamin D3. Control incubations without adrenodoxin and 
adrenodoxin reductase did not show let- or 27-hydroxylase 
activities. These results suggest that the hydroxyl group in the 
25-position hinders 24-hydroxylation by CYP27 and support 
the contention that CYP27 is a 25-hydroxyvitamin D3 24- 
hydroxylase in neither liver nor kidney. 
3.5. Biological significance 
It has recently been reported that liver mitochondrial 
CYP27 catalyzes let-hydroxylation f 25-hydroxyvitamin Dz
[14] and that let,25-dihydroxyvitamin D3 suppresses both mi- 
tochondrial et-hydroxylase activity and the expression of 
CYP27 mRNA in kidney [16]. The results of the present study 
showing that renal CYP27 catalyzes la-hydroxylation but not 
24-hydroxylation of 25-hydroxyvitamin Dz provide further 
evidence that renal let-hydroxylation might be catalyzed by 
CYP27. In fact, the results from the purification, immunopre- 
cipitation and substrate inhibition experiments indicate that 
CYP27 is responsible for most if not all of the let-hydroxylase 
activity in kidney mitochondria. However, the existence of 
another let-hydroxylase different from CYP27 cannot be com- 
pletely ruled out. All the final cytochrome P450 fractions 
showed not only the major CYP27 protein at 53 kDa but 
also a minor protein at 55 kDa on silver-stained SDS- 
PAGE. Several aboratories have estimated the Mr of their 
putative lc(-hydroxylase to be about 53-59 kDa [26-28]. 
The possibility that the 55 kDa protein might be a let- 
hydroxylase seems to be excluded, since polyclonal antibodies 
(HP3) raised against he 55 kDa protein were unable to im- 
munoprecipitate the la-  and 27-hydroxylase activities. 
The conclusion that renal CYP27 might be a major mito- 
chondrial et-hydroxylase is both supported and disfavoured 
by a study on patients with the rare inherited isease cerebro- 
tendinous xanthomatosis having defective sterol 27-hydroxyl- 
ation of bile acid intermediates [29]. On the one hand, it was 
demonstrated that extensive osteoporosis and increased risk of 
bone fractures are components of the disease; on the other, 
14 Z Araya et al.IFEBS Letters 390 (1996) 10-14 
the serum concentrations of lct,25-dihydroxyvitarnin D3 were 
not significantly lower than in healthy subjects [29]. 
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